Androgen receptors beyond prostate cancer: An old marker as a new target

Oncotarget

Volumn 6, Issue 2, 2015, Pages 592-603

  Munoz, Javier ^a   Wheler, Jennifer J ^b   Kurzrock, Razelle ^c  

^a Banner MD Anderson Cancer Center   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen receptor; Molecular abnormalities; Phase I clinical trials; Therapy

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANDROSTANOLONE; BICALUTAMIDE; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; ETOMIDATE; FLUTAMIDE; FULVESTRANT; GOSERELIN; HYDROXYFLUTAMIDE; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; MITOTANE; PLACEBO; PROGESTERONE RECEPTOR; RETINOIC ACID; TAMOXIFEN; TESTOSTERONE; TRIPTORELIN; TUMOR MARKER;

ADRENAL CORTEX CARCINOMA; ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASAL CELL CARCINOMA; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CARCINOMA; CONNECTIVE TISSUE TUMOR; DESMOID TUMOR; DIGESTIVE SYSTEM CANCER; DISEASE MARKER; DISEASE SPECIFIC SURVIVAL; DRUG EFFICACY; DRUG TARGETING; GERM CELL TUMOR; GLIOBLASTOMA; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LARYNX CARCINOMA; LEYDIG CELL OVARIAN TUMOR; LEYDIG CELL TUMOR; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NASOPHARYNX FIBROMA; NON SMALL CELL LUNG CANCER; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALIVARY GLAND CANCER; SARCOMA; SKIN CANCER; SMALL CELL LUNG CANCER; THYMOMA; THYROID CARCINOMA; UROGENITAL TRACT CANCER; UTERINE CERVIX CANCER; UTERUS CANCER; UTERUS SARCOMA; ANIMAL; DISEASE COURSE; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PROSTATIC NEOPLASMS;

ANIMALS; BIOMARKERS, TUMOR; DISEASE PROGRESSION; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84921778182     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2831     Document Type: Article

References (55)

1. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25(12):1596-605.
2. Askew EB, Gampe RT, Jr., Stanley TB, et al. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem 2007;282(35):25801-16.
3. Sandow J, von Rechenberg W, Engelbart K. Pharmacological studies on androgen suppression in therapy of prostate carcinoma. Am J Clin Oncol 1988;11 Suppl 1:S6-10.
4. Davison SL, Bell R. Androgen physiology. Semin Reprod Med 2006;24(2):71-7.
5. Clark AJ, Metherell LA. Mechanisms of disease: the adrenocorticotropin receptor and disease. Nat Clin Pract Endocrinol Metab 2006;2(5):282-90.
6. Rittmaster RS, Zwicker H, Thompson DL, et al. Androstanediol glucuronide production in human liver, prostate, and skin. Evidence for the importance of the liver in 5 alpha-reduced androgen metabolism. J Clin Endocrinol Metab 1993;76(4):977-82.
7. Valle LD, Toffolo V, Nardi A, et al. Tissue-specific transcriptional initiation and activity of steroid sulfatase complementing dehydroepiandrosterone sulfate uptake and intracrine steroid activations in human adipose tissue. J Endocrinol 2006;190(1):129-39.
8. Thomas BC, Neal DE. Androgen deprivation treatment in prostate cancer. BMJ 2013;346:e8555.
9. Lepor H. Comparison of single-agent androgen suppression for advanced prostate cancer. Rev Urol 2005;7 Suppl 5:S3-S12.
10. Lepor H, Shore ND. LHRH Agonists for the Treatment of Prostate Cancer: 2012. Rev Urol 2012;14(1-2):1-12.
11. Rick FG, Block NL, Schally AV. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. Onco Targets Ther 2013;6:391-402.
12. Gauthier S, Martel C, Labrie F. Steroid derivatives as pure antagonists of the androgen receptor. J Steroid Biochem Mol Biol 2012;132(1-2):93-104.
13. Freedland SJ, Eastham J, Shore N. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer Prostatic Dis 2009;12(4):333-8.
14. Carruba G. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem 2007;102(4):899-911.
15. Langley RE, Cafferty FH, Alhasso AA, et al. Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncol 2013;14(4):306-16.
16. Peer A, Gottfried M, Sinibaldi V, et al. Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel. Prostate 2013.
17. Salem M, Garcia JA. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer. Curr Oncol Rep 2011;13(2):92-6.
18. Gardner JR, Livingston PM, Fraser SF. Effects of Exercise on Treatment-Related Adverse Effects for Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Systematic Review. J Clin Oncol 2013.
19. Sountoulides P, Rountos T. Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management. ISRN Urol 2013;2013:240108.
20. Cannata DH, Kirschenbaum A, Levine AC. Androgen deprivation therapy as primary treatment for prostate cancer. J Clin Endocrinol Metab 2012;97(2):360-5.
21. Yap TA, Zivi A, Omlin A, et al. The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 2011;8(10):597-610.
22. Hammes SR, Levin ER. Extranuclear steroid receptors: nature and actions. Endocr Rev 2007;28(7):726-41.
23. Tombal B. What is the pathophysiology of a hormone-resistant prostate tumour? Eur J Cancer 2011;47 Suppl 3:S179-88.
24. Saraon P, Jarvi K, Diamandis EP. Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem 2011;57(10):1366-75.
25. Geller J, Albert JD. Comparison of various hormonal therapies for prostatic carcinoma. Semin Oncol 1983;10(4 Suppl 4):34-41.
26. Jacobi GH, Wenderoth UK. Gonadotropin-releasing hormone analogues for prostate cancer: untoward side effects of high-dose regimens acquire a therapeutical dimension. Eur Urol 1982;8(3):129-34.
27. Ricke WA, Wang Y, Cunha GR. Steroid hormones and carcinogenesis of the prostate: the role of estrogens. Differentiation 2007;75(9):871-82.
28. Shah S, Ryan C. Abiraterone acetate for castration resistant prostate cancer. Expert Opin Investig Drugs 2010;19(4):563-70.
29. Harris WP, Mostaghel EA, Nelson PS, et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009;6(2):76-85.
30. Hussain M, Tangen CM, Higano CS, et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. J Clin Oncol 2012;30(18_suppl).
31. Crook JM, O'Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012;367(10):895-903.
32. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375(9724):1437-46.
33. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-97.
34. DeBono JS, Fizazi K, Saad F, et al. Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. J Clin Oncol 2012;30(15_suppl).
35. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011;29(27):3651-8.
36. Wassersug RJ. Mastering emasculation. J Clin Oncol 2009;27(4):634-6.
37. Kobayashi T, Shimizu Y, Terada N, et al. Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation. Prostate 2010;70(8):866-74.
38. Wang Y, Mikhailova M, Bose S, et al. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 2008;27(56):7106-17.
39. McCall P, Gemmell LK, Mukherjee R, et al. Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br J Cancer 2008;98(6):1094-101.
40. Roychowdhury S, Chinnaiyan AM. Advancing precision medicine for prostate cancer through genomics. J Clin Oncol 2013;31(15):1866-73.
41. Recchia AG, Musti AM, Lanzino M, et al. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells. Int J Biochem Cell Biol 2009;41(3):603-14.
42. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009;15(7):2472-8.
43. Wang Y, Romigh T, He X, et al. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene 2011;30(42):4327-38.
44. Barnett CM, Heinrich MC, Lim J, et al. Genetic Profiling to Determine Risk of Relapse Free Survival in High-risk Localized Prostate Cancer. Clin Cancer Res 2013.
45. Zhang W, Haines BB, Efferson C, et al. Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors. Transl Oncol 2012;5(6):422-9.
46. Mulder E, van Loon D, de Boer W, et al. Mechanism of androgen action: recent observations on the domain structure of androgen receptors and the induction of EGF-receptors by androgens in prostate tumor cells. J Steroid Biochem 1989;32(1B):151-6.
47. Fiorelli A, Ricciardi C, Pannone G, et al. Interplay between steroid receptors and neoplastic progression in sarcoma tumors. J Cell Physiol 2011;226(11):2997-3003.
48. Chia KM, Liu J, Francis GD, et al. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia 2011;13(2):154-66.
49. Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 2008;10(6):542-8.
50. Naderi A, Chia KM, Liu J. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Res 2011;13(2):R36.
51. Wang Y, Yang J, Gao Y, et al. Reciprocal regulation of 5alpha-dihydrotestosterone, interleukin-6 and interleukin-8 during proliferation of epithelial ovarian carcinoma. Cancer Biol Ther 2007;6(6):864-71.
52. Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011;71(18):6019-29.
53. Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm SM,. Biologic and clincial significance of androgen receptor varianrts n castration resistant prostate cancer. Endocr Relat Cancer 2014: Aug;21(4):T87-T103.
54. McNamara KM1, Moore NL1, Hickey TE1, Sasano H1, Tilley WDComplexities of androgen receptor signalling in breast cancer. Endocr Relat Cancer. 2014 Aug;21(4):T161-81. doi: 10.1530/ERC-14-0243. Epub 2014 Jun 2.
55. Mechlin CW, Frankel J, McCullough A. Coadministration of anastrozole sustains therapeutic testosterone levels in hypogonadal men undergoing testosterone Pellet insertion. J Sex Med 2013.